MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Arbutus Biopharma Corp

Abierto

3.29 0.3

Resumen

Variación precio

24h

Actual

Mínimo

3.25

Máximo

3.34

Métricas clave

By Trading Economics

Ingresos

7.2M

-13M

Ventas

235K

1.6M

BPA

-0.1

Margen de beneficio

-796.188

Empleados

44

EBITDA

7.2M

-12M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+49.7% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-28M

615M

Apertura anterior

2.99

Cierre anterior

3.29

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Arbutus Biopharma Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 abr 2025, 23:54 UTC

Acciones populares

Stocks to Watch: Alphabet, Intel, AppFolio

24 abr 2025, 23:51 UTC

Charlas de Mercado

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

24 abr 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24 abr 2025, 23:37 UTC

Principales Noticias

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24 abr 2025, 23:36 UTC

Principales Noticias

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24 abr 2025, 23:13 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- Update

24 abr 2025, 23:09 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24 abr 2025, 23:02 UTC

Adquisiciones, fusiones, absorciones

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24 abr 2025, 22:51 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24 abr 2025, 22:48 UTC

Principales Noticias

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24 abr 2025, 22:47 UTC

Charlas de Mercado

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24 abr 2025, 22:38 UTC

Charlas de Mercado
Ganancias

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24 abr 2025, 22:24 UTC

Ganancias

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24 abr 2025, 22:24 UTC

Charlas de Mercado
Ganancias

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24 abr 2025, 22:23 UTC

Ganancias

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

24 abr 2025, 22:11 UTC

Charlas de Mercado
Ganancias

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24 abr 2025, 22:09 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24 abr 2025, 22:00 UTC

Charlas de Mercado
Ganancias

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24 abr 2025, 21:39 UTC

Principales Noticias

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24 abr 2025, 21:24 UTC

Principales Noticias
Ganancias

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24 abr 2025, 21:23 UTC

Principales Noticias
Ganancias

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24 abr 2025, 21:04 UTC

Ganancias

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24 abr 2025, 21:03 UTC

Ganancias

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24 abr 2025, 21:02 UTC

Ganancias

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Comparación entre iguales

Cambio de precio

Arbutus Biopharma Corp Esperado

Precio Objetivo

By TipRanks

49.7% repunte

Estimación a 12 meses

Media 5 USD  49.7%

Máximo 5 USD

Mínimo 5 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arbutus Biopharma Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

3.15 / 3.34Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.